Abiopharma

🔍 Forster Eliot (Executive)

Company: Protalix BioTherapeutics, Inc. (PLX)

Report Date: 2025-09-03

Detailed Transactions and Holdings:

• Acquired 7,500 shares of Common Stock (Direct)
  Date: 2025-09-03 | Code: A | equity_swap_involved: 0 | shares_owned_after: 7,500.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 15,000 shares of Stock Options (Right to Buy) at $1.64 per share (Derivative)
  Date: 2025-09-03 | Code: A | Expires: 2035-09-03 | equity_swap_involved: 0 | shares_owned_after: 15,000.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.
• F2: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.
• F3: Does not include options to purchase 85,715 shares of common stock at an exercise price equal to $1.75 per share that expire on September 14, 2033,